Osivax shifts to combination strategy after Phase 2b flu vaccine setback

Osivax, a French biotech, reported that its lead influenza vaccine candidate did not meet primary endpoints in a Phase 2b study.

The trial, which evaluated the vaccine as a standalone product, showed insufficient immune response compared with expectations, leading the company to label the result a failure.

In response, Osivax announced it will pursue a combination approach, pairing its candidate with existing seasonal flu shots to potentially boost efficacy.

The company remains optimistic that the revised strategy could salvage the program and move it forward in future studies.